Currently, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly employed for staging of patients with intermediate- and high-risk primary prostate cancer, as well as in patients experiencing recurrence after treatment with curative intent [1, 2]. The gene discussed is FOLH1; the disease is prostate carcinoma.